The Lp(a) Reckoning: Why the 2026 ACC/AHA Guidelines Just Rewrote the Rules of Heart Disease Prevention

For thirty years, cardiology has chased a moving target. We measured LDL cholesterol, refined statins, layered on PCSK9 inhibitors, and watched cardiovascular mortality fall. Yet roughly one in five heart attacks still arrives in patients whose lipid panels looked clean, whose risk calculators read low, and whose lifestyles offered no obvious culprit. Behind a quiet but extraordinary number of those events sits a lipoprotein particle most patients have never heard of: lipoprotein(a), or Lp(a).

Presented By Our Partners

That changed on March 13, 2026, when the American College of Cardiology, the American Heart Association, and ten partner societies released the most consequential cholesterol guideline in nearly a decade. The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia did something American medicine had never done before. It recommended that every adult in the United States have their Lp(a) measured at least once in a lifetime as part of standard cardiovascular risk assessment.

The shift is bigger than a new checkbox on a lab order. It reframes cardiovascular prevention as a genetic question that begins decades before symptoms appear. It pulls a long-neglected molecule into the same conversation as LDL, blood pressure, and tobacco. And it arrives at the precise moment when four pharmaceutical programs are racing to deliver the first medicines that can actually lower Lp(a), with cardiovascular outcomes data expected before the end of this year.

This is the story of how a particle first identified in 1963 went from a curiosity to the cornerstone of precision cardioprevention, and what it means for anyone who plans to be alive in 2040.

What Lp(a) Actually Is, and Why It Matters

Lp(a) is a low density lipoprotein particle with an unusual passenger. Bolted to its surface is a protein called apolipoprotein(a), encoded by the LPA gene on chromosome 6. The molecule looks similar to plasminogen, a protein the body uses to dissolve blood clots, and it appears to interfere with normal clot resolution. It also carries oxidized phospholipids that drive arterial inflammation. The combination is unusually atherogenic. Population studies have linked elevated Lp(a) to coronary artery disease, ischemic stroke, peripheral artery disease, and a remarkable and underappreciated condition: calcific aortic valve stenosis.

Roughly one in five adults worldwide carries an Lp(a) level above the high risk threshold of 50 milligrams per deciliter, often expressed in newer assays as 125 nanomoles per liter. Levels are roughly ninety percent genetically determined, set at birth, and remarkably stable across a lifetime. Diet barely moves them. Exercise does not move them. Statins can paradoxically nudge them up by ten to twenty percent. For decades that immovability was a clinical dead end. If you could not modify the marker, why measure it?

The 2026 guideline answers that question by changing how a single Lp(a) measurement is used. Even without a drug to lower the level, a high Lp(a) result moves a patient up the risk ladder, sharpens the case for aggressive LDL reduction, and triggers cascade screening of first degree relatives. The Family Heart Foundation has called it the highest yield single test in preventive cardiology, capable of identifying inherited risk with one tube of blood that a person ever needs to draw.

The Writing Committee and the Logic of Universal Screening

The guideline was chaired by Roger S. Blumenthal of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, with Pamela B. Morris of the Medical University of South Carolina serving as vice chair. The writing committee assembled clinicians from cardiology, endocrinology, family medicine, pharmacy, nursing, and primary care prevention, signaling a deliberate pivot away from cholesterol management as a subspecialty concern and toward a population health problem.

Their case for universal Lp(a) screening rested on three pillars. First, the prevalence is high enough that targeted testing leaves too many people undiagnosed. Roughly sixty to seventy percent of adults with elevated Lp(a) have no family history that would flag them for selective testing under older guidance. Second, the test is inexpensive, widely available, and only needs to be performed once. Third, the clinical actions triggered by a positive result are now meaningful. A patient with elevated Lp(a) can be treated to lower LDL targets, screened earlier and more often for subclinical atherosclerosis, and enrolled in clinical trials of investigational Lp(a) lowering therapies.

European cardiology guidelines and the Canadian Cardiovascular Society had already moved in this direction in 2019 and 2021 respectively. The 2026 U.S. guideline brings American practice into alignment with international consensus and, in some respects, overtakes it by integrating Lp(a) into a new generation of risk equations.

PREVENT: The Risk Calculator That Replaces the Pooled Cohort Equations

The 2026 guideline retires the 2013 era Pooled Cohort Equations and adopts the AHA PREVENT-ASCVD risk equations, released by the American Heart Association in 2023. PREVENT stands for Predicting Risk of Cardiovascular Disease Events. The model was trained on more than 6.6 million contemporary patients drawn from 46 datasets across the United States and is engineered to estimate both 10 year and 30 year risk of atherosclerotic cardiovascular disease in adults aged 30 to 79.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

What makes PREVENT different is the variables it pulls in. The model accepts traditional inputs such as age, blood pressure, cholesterol, smoking status, and diabetes, but also incorporates kidney function via estimated glomerular filtration rate, body mass index, and, optionally, urinary albumin to creatinine ratio, hemoglobin A1c, and social deprivation index. It does not require race as an input, addressing a long standing critique of the older Pooled Cohort Equations.

The 30 year horizon is the philosophical heart of the new guideline. Cardiology has spent two decades focused on 10 year risk windows that systematically undercount the lifetime exposure of younger adults to atherogenic lipoproteins. A 35 year old with a moderate LDL of 130 and an Lp(a) of 200 nmol/L may have a 10 year risk that looks reassuring. The 30 year window tells a very different story. The guideline calls this an "earlier and lower for longer" framework, and it is informed by Mendelian randomization studies, including work from Brian Ference at the University of Cambridge, showing that cumulative LDL exposure across a lifetime is a more powerful determinant of coronary disease than any single time point.

What the Guideline Actually Recommends

The 2026 document makes nine major changes worth knowing. Universal Lp(a) screening is the headline, but the surrounding architecture matters.

The guideline recommends universal lipid screening for children between ages 9 and 11, codifying a practice many pediatric cardiologists had already adopted but the field had not formally endorsed. It restores explicit LDL cholesterol treatment targets, after the 2018 guideline had moved toward a percent reduction model that clinicians found difficult to operationalize. For patients with established atherosclerotic disease, the target is now less than 55 mg/dL, with consideration of less than 40 mg/dL for very high risk subgroups. For primary prevention in patients with multiple risk factors, the target is less than 70 mg/dL.

The guideline expands the role of apolipoprotein B as a measurement of choice in patients with elevated triglycerides or metabolic syndrome, situations where LDL cholesterol calculated by the Friedewald equation systematically underestimates the true particle burden. It positions PCSK9 inhibitors, including alirocumab and evolocumab, as first line add on therapy for patients who cannot reach LDL targets on maximum tolerated statins. It carves out a clearer pathway for bempedoic acid, an ATP citrate lyase inhibitor approved in 2020, in statin intolerant patients. And it modestly endorses icosapent ethyl in patients with elevated triglycerides and established cardiovascular disease, on the strength of the REDUCE-IT trial.

For patients with elevated Lp(a), the guideline is more cautious than some advocates had hoped. It does not yet recommend a specific Lp(a) lowering therapy outside of clinical trials, because no agent has finished a cardiovascular outcomes trial. It recommends instead that Lp(a) elevation be used to intensify management of every other modifiable risk factor: aggressive LDL reduction, blood pressure control, glycemic control, smoking cessation, and adequate physical activity. The implicit logic is that if you cannot lower the genetic floor, you should lower everything sitting on top of it.

The Drug Pipeline About to Catch the Guideline

The most striking feature of the 2026 guideline is its timing. Four investigational therapies that lower Lp(a) by 70 to 94 percent are in late stage trials, and their results begin arriving this year.

Pelacarsen is an antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis. It binds the messenger RNA for apolipoprotein(a) and blocks its production in the liver. The pivotal Phase 3 Lp(a) HORIZON trial, designed by Sotirios Tsimikas of the University of California San Diego and Steven Nissen of the Cleveland Clinic, enrolled 8,323 patients with established cardiovascular disease and Lp(a) at least 70 mg/dL. Patients receive monthly subcutaneous injections of 80 milligrams of pelacarsen or placebo. Phase 2 data published in the New England Journal of Medicine in 2020 showed reductions in Lp(a) of up to 80 percent. Phase 3 topline cardiovascular outcomes are expected in the first half of 2026. Regulatory submissions to the U.S. Food and Drug Administration and the European Medicines Agency are planned for the second half of the year.

Olpasiran is a small interfering RNA therapy developed by Amgen. It silences the LPA gene directly in hepatocytes and is administered as a subcutaneous injection every 12 weeks. The Phase 3 OCEAN(a)-Outcomes trial enrolled approximately 7,000 patients with established atherosclerotic cardiovascular disease and Lp(a) at least 200 nmol/L. Phase 2 data, published in the New England Journal of Medicine in 2022 by Michelle O’Donoghue of Brigham and Women’s Hospital and the TIMI Study Group, showed reductions in Lp(a) above 95 percent at the highest dose. The trial is expected to complete in December 2026.

Lepodisiran, from Eli Lilly, is another siRNA agent with a similar mechanism but a longer dosing interval, potentially as infrequent as every six months. Muvalaplin, also from Eli Lilly, is an oral small molecule that prevents apolipoprotein(a) from binding to LDL. If proven effective in outcomes trials, muvalaplin would be the first oral Lp(a) lowering therapy and a fundamentally different commercial proposition.

If even one of these agents demonstrates a clinically meaningful reduction in major adverse cardiovascular events, the 2026 guideline will need to be revised within a year. Field consensus is that the guideline was deliberately structured to be ready for that update. Universal Lp(a) screening, in other words, is not just a recommendation about a test. It is the infrastructure layer for an entirely new therapeutic class.

What This Means For You

Lp(a) is the rare lab value that meets two unusual conditions at once. It is high impact, because it independently predicts heart attack, stroke, and aortic valve disease across a lifetime. And it is a one time test, because levels are set genetically and do not meaningfully change.

If you have never had your Lp(a) measured, the 2026 guideline now formally recommends that you do, ideally as part of your next annual lipid panel. Ask your physician to add Lp(a) to the order. Most major labs now report results in both mass units (mg/dL) and molar units (nmol/L). The cutoffs that matter are roughly 50 mg/dL or 125 nmol/L for high risk, and above 180 mg/dL or 430 nmol/L for very high risk.

If your Lp(a) is elevated, the immediate clinical implications are concrete. You should be treated to a lower LDL target than your absolute risk score might otherwise suggest. You should have your blood pressure managed tightly, ideally below 130/80. You should ask your physician about coronary artery calcium scoring after age 40, which provides a direct measure of subclinical atherosclerosis. And you should consider clinical trial enrollment if you meet eligibility criteria, both because emerging therapies may benefit you and because participation accelerates the evidence base for everyone else.

If your Lp(a) is elevated, you should also tell your first degree relatives. Lp(a) is co-dominantly inherited, meaning your parents, siblings, and children each have a meaningfully higher chance of carrying the same risk. Cascade screening of families is one of the highest yield interventions in all of preventive cardiology, comparable in cost effectiveness to colon cancer screening.

If your Lp(a) is low, the test has still been worth doing. You have ruled out a major and otherwise hidden risk factor, and you and your physician can focus attention on the modifiable factors that remain. A low Lp(a) is not a license to ignore LDL, blood pressure, glucose, or fitness, but it does mean that the genetic floor of your cardiovascular risk is more favorable than average.

The deeper lesson of the 2026 guideline is that cardiovascular prevention is becoming a precision discipline. The era of treating every patient as an average is ending. Risk equations now incorporate kidney function, social context, and a 30 year horizon. Treatment targets are stratifying by genetic background. And for the first time, a lifelong exposure that we could only measure but never modify is about to become modifiable. The patients who benefit most will be the ones who have already been tested, who already know their number, and who are ready to act on the answer.

The lab order takes thirty seconds. The follow up consultation takes fifteen minutes. The lifetime of decisions it shapes is forty years long. Of all the items in the new guideline, this is the one that costs the least and matters the most. Make the order.

References and Further Reading

The 2026 Guideline on the Management of Dyslipidemia was published in Circulation and the Journal of the American College of Cardiology on March 13, 2026. The PREVENT equations were published in Circulation in November 2023 by Sadiya Khan of Northwestern University and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Key Lp(a) therapeutic trials are registered at ClinicalTrials.gov under identifiers NCT04023552 (Lp(a) HORIZON), NCT05581303 (OCEAN(a)-Outcomes), NCT06292013 (ACCLAIM-Lp(a)), and NCT05900141 (KRAKEN). Family cascade screening protocols are available through the Family Heart Foundation. The Cleveland Clinic, Mayo Clinic, Johns Hopkins Ciccarone Center, and University of California San Diego maintain Lp(a) specialty clinics for high risk patients.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.